May 6, 2025: Wegovy May Soon Be Available as a Pill to Treat Obesity-Related Conditions On May 2, 2025, Novo Nordisk announced that the U.S
10.1158/0008-5472.CAN-03-2868 84 RizzolloF.MoreS.VangheluweP.AgostinisP
doi:10.3324/haematol.2010.039396
Does your program have a specific policy on GLP-1 medications? Do you require a washout period before embryo transfer, and how long is it? If I stop, what symptoms should I expect, and how should I manage them before the transfer? How will you coordinate with my prescribing clinician on the stop date? If I plan to pump breast milk after delivery, when can I restart my medication? What side effects such as nausea or dehydration should I report right away? Tip: At Physicians Surrogacy, our in-house OB/GYN team can conduct peer-to-peer consultations with your prescribing physician something most agencies cannot offer because they are run by non-medical staff
Because of this, both drugs are expected to work in the same way for weight loss
For patients considering GLP-1 therapy or those already receiving treatment, identifying how the medication affects your body helps inform dose adjustments, side effect management, and long-term sustainability